News

According to a regulatory filing, Sun Pharma will buy the entire issued and outstanding share capital of Innovcare Lifesciences via a cash transaction. The company expects to close

The approval follows a positive finding in the pivotal IRAKLIA Phase III study, which demonstrated non-inferior efficacy and pharmacokinetics compared with the intravenous (IV) formulation. It also marks

The partnership will bring together Voro Therapeutics’ tumour-activated biologics platform with Alloy Therapeutics’ cluster of differentiation 3 (CD3) antibodies and multispecific engineering capabilities. This joint effort aims to

The deal value comprises an upfront payment and further payments tied to the achievement of future clinical and regulatory milestones. The proposed acquisition will add several anti-inflammatory candidates

The collaboration involves up to $56m in upfront payments to AbCellera for the first two research programmes, with an additional $28m payable if a third programme begins within

Executives from both organisations, including LG AI Research head Woohyung Lim and D&D Pharmatech CEO Seulki Lee, attended the event to formalise the partnership. The project focuses on

The agreement broadens AviadoBio’s existing rights, which were previously limited to the development of gene therapies for neurological diseases under a 2020 agreement. The vMiX platform leverages adeno-associated

Under the deal, Simulations Plus shareholders will receive $18.50 per share, representing a 26% premium to the 60-day volume-weighted average price as of 15 June 2026. The company’s

The FDA granted the status to alixorexton for idiopathic hypersomnia while the EC approved the designation for narcolepsy. In the US, the ODD offers incentives such as tax